ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of

ADDEX THERAPEUTICS LTD

INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

Therapeutics Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Balance

as of June 30, 2022, and December 31, 2021

The accompanying notes form an integral part of these consolidated

financial statements.

Therapeutics Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Comprehensive Loss

for the three-month and six-month periods ended

June 30, 2022 and 2021

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

for the six-month periods ended June 30, 2022

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Interim Condensed Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

for the three-month period ended June 30, 2022

The accompanying notes form an integral part of

these consolidated financial statements.

Addex Therapeutics Interim Condensed

Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

of Changes in Equity

the three-month period ended June 30, 2022 (2/2)

The accompanying notes form an integral part of

these consolidated financial statements.

Addex Therapeutics Interim Condensed

Consolidated Financial Statements

Unaudited Interim Condensed Consolidated Statements

for the six-month periods ended June 30, 2022

The accompanying notes form an integral part of

these consolidated financial statements.

Therapeutics Interim Condensed Consolidated Financial Statements Notes

Unaudited Notes to the Interim Condensed Consolidated

Financial Statements

for the three-month and six-month periods ended

(Amounts in Swiss francs)

1. General information

Addex Therapeutics Ltd (the "Company"), formerly Addex

Pharmaceuticals Ltd, and its subsidiaries (together, the "Group") are a clinical stage pharmaceutical group applying its leading

allosteric modulator drug discovery platform to discovery and development of small molecule pharmaceutical products, with an initial focus

on central nervous system disorders.

The Company is a Swiss stockholding corporation domiciled c/o Addex

Pharma SA, Chemin des Aulx 12, CH1228 Plan-les-Ouates, Geneva, Switzerland and the parent company of Addex Pharma SA, Addex Pharmaceuticals

France SAS and Addex Pharmaceuticals Inc. registered in Delaware with its principal business location in San Francisco, California, United

States. Its registered shares are traded at the SIX, Swiss Exchange, under the ticker symbol ADXN. On January 29, 2020, the Group listed

on the Nasdaq Stock Market, American Depositary Shares (ADSs) under the symbol "ADXN", without a new issuance of securities.

ADSs represents shares that continue to be admitted to trading on SIX Swiss Exchange.

These condensed consolidated financial statements have been approved

for issuance by the Board of Directors on 17 August, 2022.

2. Basis of preparation

These interim condensed consolidated financial statements

for the three-month and six-month periods ended June 30, 2022, have been prepared under the historic cost convention and in

accordance with IAS 34 "Interim Financial Reporting" and are presented in a format consistent with the consolidated

financial statements under IAS 1 "Presentation of Financial Statements". However, they do not include all of the notes

that would be required in a complete set of financial statements. Thus, this interim financial report should be read in conjunction

with the consolidated financial statements for the year ended December 31, 2021.

Interim financial results are not necessarily indicative of

results anticipated for the full year. The preparation of these unaudited condensed consolidated interim financial statements made

in accordance with IAS 34 requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities

and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and

expenses during the reporting period. Although these estimates are based on management's best knowledge of current events and

actions, actual results ultimately may differ from those estimates. The areas involving a higher degree of judgment which are

significant to the interim condensed consolidated financial statements are disclosed in note 4 to the consolidated financial

statements for the year ended December 31, 2021.

A number of new or amended standards and interpretations became applicable

for financial periods beginning on or after January 1, 2022. The Group noted that the latter did not have a material impact on the Group's

financial position or disclosures made in the interim condensed consolidated financial statements.

Due to rounding, numbers presented throughout these Interim

condensed consolidated financial statements may not add up precisely to the totals provided. All ratios and variances are

calculated using the underlying amount rather than the presented rounded amount.

3. Critical accounting estimates and judgments

The Group makes estimates and assumptions concerning the future. These

estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of

future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by definition, seldom

equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying

amounts of assets and liabilities or may have had a significant impact on the reported results are disclosed below:

Group's accounts are prepared on a going concern basis. To date, the Group has financed its cash requirements primarily from

share issuances and licensing certain of its research and development stage products. The Group is a development-stage enterprise

and is exposed to all the risks inherent in establishing a business. The Group expects that its existing cash and cash equivalents,

at the issuance date of these unaudited condensed consolidated interim financial statements, will be sufficient to fund its

operations and meet all of its obligations as they fall due, through the end of the first half of 2023. These factors individually

and collectively indicate that a material uncertainty exists that may cast substantial doubt about the Group's ability to continue

as a going concern for one year from the date of issuance of these unaudited interim condensed consolidated financial

statements. The future viability of the Group is dependent on its ability to raise additional capital through public or private